Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Milita...
August 15 2018 - 11:46AM
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix)
announced today that it will be presenting findings and
retrospective analyses from the Phase 3 HONOR study and Phase 2
AtEase Study in a poster, at the 2018 Military Health System
Research Symposium (MHSRS) being held August 20 – 23, 2018, in
Kissimmee, Fla.
|
|
Details of poster presentation at MHSRS |
|
|
Title: |
Differential Treatment Effects of a Sublingual Formulation of
Cyclobenzaprine (TNX-102 SL*) on Dissociative Symptoms of
Derealization and Depersonalization in a Military-Related PTSD
Population: Retrospective Analysis of a Double-Blind Randomized
Study |
|
|
Poster Session: |
Poster
Session 1 |
|
|
Poster Discussion Session: |
Innovations in PTSD Treatment Research |
|
|
Date and Time: |
Tuesday,
August 21, 2018, 10:00 a.m. -12:00 p.m. ET |
|
|
Abstract Number: |
MHSRS-18-1970 |
|
Presenter: Gregory M. Sullivan, M.D., Chief
Medical Officer, Tonix Pharmaceuticals Holdings Corp. |
|
*TNX-102 SL is an investigational New Drug and has not been
approved for any indications. |
|
|
About Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical company focused on
discovering and developing pharmaceutical products to treat serious
neuropsychiatric conditions and biological products to improve
biodefense through potential medical counter-measures. Tonix is
developing TNX-102 SL, or Tonmya®#, which has been granted
Breakthrough Therapy designation as a bedtime treatment for PTSD.
TNX-102 SL is also being developed as a bedtime treatment for
agitation in Alzheimer’s disease under a separate IND to support a
Phase 2, potential pivotal efficacy study. TNX-102 SL
for agitation in Alzheimer’s disease is a Fast Track development
program. TNX-601 (tianeptine oxalate) is in the pre-IND
application stage, also for the treatment of PTSD but by a unique
mechanism and designed for daytime dosing. Tonix’s lead biologic
candidate, TNX-801, is a potential smallpox-preventing vaccine
based on a live synthetic version of horsepox virus, currently in
the pre-IND application stage.
#Tonmya has been conditionally accepted by the FDA as the
proposed trade name for TNX-102 SL (cyclobenzaprine HCl sublingual
tablets) for PTSD.
This press release and further information about Tonix can be
found at www.tonixpharma.com.
Forward Looking
Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on Tonix's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, risks related to
failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations; our need for additional financing;
uncertainties of patent protection and litigation; uncertainties of
government or third party payor reimbursement; limited research and
development efforts and dependence upon third parties; and
substantial competition. As with any pharmaceutical under
development, there are significant risks in the development,
regulatory approval and commercialization of new products. Tonix
does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk factors
set forth in the Annual Report on Form 10-K for the year ended
December 31, 2017, as filed with the Securities and Exchange
Commission (the “SEC”) on March 9, 2018, and periodic reports filed
with the SEC on or after the date thereof. All of Tonix's
forward-looking statements are expressly qualified by all such risk
factors and other cautionary statements. The information set forth
herein speaks only as of the date thereof.
Contacts
Jessica Morris (corporate)Tonix
Pharmaceuticalsinvestor.relations@tonixpharma.com(212) 980-9159
Scott Stachowiak (media)Russo
Partnersscott.stachowiak@russopartnersllc.com (646) 942-5630
Peter Vozzo (investors)Westwicke
Partnerspeter.vozzo@westwicke.com (443) 213-0505
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Sep 2023 to Sep 2024